Free Trial

LLA.L,0P0001T9GN,0 (LLA) Competitors

GBX 3 -2.00 (-40.00%)
As of 07:16 AM Eastern

LLA vs. IDHC, DXRX, AGL, YGEN, ABDX, PRM, GDR, VRCI, GENI, and DMTR

Should you be buying LLA.L,0P0001T9GN,0 stock or one of its competitors? The main competitors of LLA.L,0P0001T9GN,0 include Integrated Diagnostics (IDHC), Diaceutics (DXRX), ANGLE (AGL), Yourgene Health (YGEN), Abingdon Health (ABDX), Proteome Sciences (PRM), genedrive (GDR), Verici Dx (VRCI), GENinCode (GENI), and Deepmatter Group (DMTR). These companies are all part of the "diagnostics & research" industry.

LLA.L,0P0001T9GN,0 vs.

Integrated Diagnostics (LON:IDHC) and LLA.L,0P0001T9GN,0 (LON:LLA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, community ranking, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

Integrated Diagnostics received 56 more outperform votes than LLA.L,0P0001T9GN,0 when rated by MarketBeat users.

CompanyUnderperformOutperform
Integrated DiagnosticsOutperform Votes
56
65.12%
Underperform Votes
30
34.88%
LLA.L,0P0001T9GN,0N/AN/A

Integrated Diagnostics has a net margin of 17.21% compared to LLA.L,0P0001T9GN,0's net margin of 0.00%. Integrated Diagnostics' return on equity of 30.45% beat LLA.L,0P0001T9GN,0's return on equity.

Company Net Margins Return on Equity Return on Assets
Integrated Diagnostics17.21% 30.45% 9.69%
LLA.L,0P0001T9GN,0 N/A -48.59%-27.28%

Integrated Diagnostics has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500. Comparatively, LLA.L,0P0001T9GN,0 has a beta of -0.3, meaning that its stock price is 130% less volatile than the S&P 500.

Integrated Diagnostics has higher revenue and earnings than LLA.L,0P0001T9GN,0. LLA.L,0P0001T9GN,0 is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Integrated Diagnostics£23.29T0.00£4.01T£0.0313.31
LLA.L,0P0001T9GN,0N/AN/A-£4.47M-£0.12-25.00

In the previous week, Integrated Diagnostics had 1 more articles in the media than LLA.L,0P0001T9GN,0. MarketBeat recorded 1 mentions for Integrated Diagnostics and 0 mentions for LLA.L,0P0001T9GN,0. Integrated Diagnostics' average media sentiment score of 0.67 beat LLA.L,0P0001T9GN,0's score of 0.00 indicating that Integrated Diagnostics is being referred to more favorably in the media.

Company Overall Sentiment
Integrated Diagnostics Positive
LLA.L,0P0001T9GN,0 Neutral

43.0% of Integrated Diagnostics shares are held by institutional investors. Comparatively, 5.4% of LLA.L,0P0001T9GN,0 shares are held by institutional investors. 34.0% of Integrated Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Integrated Diagnostics beats LLA.L,0P0001T9GN,0 on 13 of the 13 factors compared between the two stocks.

Get LLA.L,0P0001T9GN,0 News Delivered to You Automatically

Sign up to receive the latest news and ratings for LLA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LLA vs. The Competition

MetricLLA.L,0P0001T9GN,0Diagnostics & Research IndustryMedical SectorLON Exchange
Market CapN/A£786.60M£5.33B£2.62B
Dividend YieldN/A5.44%5.21%5.05%
P/E Ratio-25.002.0826.71129.34
Price / SalesN/A543.73386.13221,585.85
Price / CashN/A11.4238.2528.03
Price / Book0.112.516.773.79
Net Income-£4.47M£286.34B£3.23B£5.88B
7 Day PerformanceN/A5.02%1.80%0.62%
1 Month PerformanceN/A2.57%11.10%22.12%
1 Year PerformanceN/A-10.28%17.11%120.96%

LLA.L,0P0001T9GN,0 Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LLA
LLA.L,0P0001T9GN,0
N/AGBX 3
-40.0%
N/AN/A£0.00N/A-25.0015Gap Down
High Trading Volume
IDHC
Integrated Diagnostics
N/AGBX 0.35
flat
N/A+14.3%£10.30B£23.29T13.016,692
DXRX
Diaceutics
1.5748 of 5 stars
GBX 130.90
-0.8%
GBX 160
+22.2%
+13.9%£110.47M£26.08M-38.82151News Coverage
Gap Down
High Trading Volume
AGL
ANGLE
1.2615 of 5 stars
GBX 8.54
+10.2%
GBX 40
+368.4%
-53.7%£27.52M£2.44M-1.26650
YGEN
Yourgene Health
N/AN/AN/AN/A£16.43M£29.67M-51.50253
ABDX
Abingdon Health
N/AGBX 6.36
+4.3%
N/A-42.9%£12.32M£3.84M-15.4784Gap Down
PRM
Proteome Sciences
N/AGBX 3.05
-6.4%
N/A-2.2%£9.00M£10.88B-2.21240Gap Up
GDR
genedrive
N/AGBX 1.36
-2.4%
N/A-18.7%£7.73M£1.50M-0.3843
VRCI
Verici Dx
N/AGBX 1.25
-9.1%
N/A-85.1%£3.79M£5.91M-0.7219Gap Down
GENI
GENinCode
N/AGBX 1.69
+9.0%
N/A-80.9%£3.00M£2.67M-0.492,300News Coverage
Gap Up
DMTR
Deepmatter Group
N/AN/AN/AN/A£1.33M£1.04M-0.11N/AGap Down

Related Companies and Tools


This page (LON:LLA) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners